Navigation Links
Answerthink and LORENZ Life Sciences Group Announce Strategic,Alliance for the SAP Life Science Industry

bles companies to achieve world-class business performance. By leveraging the comprehensive database of The Hackett Group, Answerthink's business and technology solutions help clients significantly improve performance and maximize returns on technology investments. Capabilities include benchmarking, business transformation, business applications, business intelligence, and offshore application development and support. Founded in 1997, Answerthink has offices throughout the United States and in Europe and Asia. Answerthink was named the SAP 2006 SME Partner of the Year.

About LORENZ Life Sciences Group

LORENZ Life Sciences Group (www.lorenz.cc) develops and markets software solutions for the Life Sciences market. LORENZ's solutions are geared specifically for submission assembly, review, publishing, validation and management. As the number one supplier of submission management systems in the world for US, European and Japanese submissions, LORENZ is currently the market leader in producing eCTDs. With over 100 installations in 20 countries, LORENZ has built a reputable customer base.

Copyright (C) 2007 Answerthink, Inc. All rights reserved. Answerthink and EzLifeSciences as well as their respective logos are trademarks or registered trademarks of Answerthink, Inc.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risks, uncertainties and other factors that may cause Answerthink's actual results, performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statements. Factors that impact such forward-looking statements include, among others, the ability of the alliance or the products, services, or practices mentioned in this release to deliver the desired effect, our ability to effectively integrate acquisitions into our operations, our ability to
'"/>




Page: 1 2 3

Related medicine technology :

1. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
6. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
7. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
8. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus
9. Human Genome Sciences Announces Positive Final Results Of Phase 2b Trial of Albuferon
10. Oculus Innovative Sciences Microcyn Technology Presented in Poster at European Wound Management Association Conference
11. IR BioSciences Announces Promising Data from Study of Its Compound Homspera

Post Your Comments:
(Date:11/6/2009)...SAN DIEGO, Nov. 6 NexBio Inc., in ...isease Control and Prevention (CDC), St. Louis Uni...d today the publication of two articles in the pee...studies suggest that DAS181 (Fludase ® ) may ...t and prevention of the Pandemic Influenza A(H1N1)...
(Date:11/6/2009)... PARIS, November 6 , -... Linezolid for the,Treatment of Multi-Resistant St...ovexel, a speciality pharmaceutical company focuse...otics designed to overcome the significant global,...hat its most advanced oral,antibacterial NXL103 (f...
(Date:11/5/2009)...POINT RICHMOND, Calif., Nov. 5 /PRNewswire-FirstCa...SPT ), a specialty pharmaceutical company focused ...etary products that address important therapeutic ...d it will host a webcast and teleconference with m...results on Thursday, November 12, 2009, at 5:00 p....
Breaking Medicine Technology:NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 2NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 3NexBio(R) Publishes Two Articles Showing DAS181 (Fludase(R)*) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses 4Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Transcept Pharmaceuticals to Report Third Quarter 2009 Results and Host Conference Call on November 12 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 1Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 2Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 3Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 4Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 5Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 6Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 7Study Published in The Lancet Showed Significant Survival Benefit for Patients Facing Deadly Form of Lung Cancer 57732 8Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 1Antigen Discovery Inc Awarded Grant for Chlamydia Vaccine Development 14163 2Life Science Firms are Turning to Firmex to do Deals Online 14161 1Life Science Firms are Turning to Firmex to do Deals Online 14161 2Life Science Firms are Turning to Firmex to do Deals Online 14161 3
... PCOP ), an innovator in the discovery and develo...announced that Schering-Plough has,initiated a Pha...8115, a,compound identified from the collaboration...evaluated as a potential treatment for respiratory...ilestone payment from,Schering-Plough as a result ...
...Phase -, WALTHAM, Mass., Sept. 25 Arbios Systems...its clinical trial strategy for,the SEPET(TM) Live...pre-pivotal phase meeting with the US Food and Dru...Arbios and the FDA,s Office for Device Evaluation,...g receipt of a final,report, SEPET(TM) has met the...
Other Medicine Technology:Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 2Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 3Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate 4Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 2Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 3Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial 4
(Date:11/9/2009)... Only 5 percent of seniors have changed Medicare...better service and improved coverage among biggest...eason nears , , Bellevill...cent of seniors have changed their Medicare plan s...rcent) report they are likely to or are considerin...
(Date:11/9/2009)...ifted young athletes are under increasing pressure...Loyola University Health System study of 519 junio...n increases the risk of injury. Researchers who an...iation junior competition found that players who s...draw from tournaments for medical reasons, typical...
(Date:11/8/2009)...8 Jon O,Brien, presiden...atement about the passage of HR 3962: ,, "Beha...ers a lot about core values. We in the prochoice c...o overcome the struggles ordinary Americans have m...nnot afford basic healthcare or have to choose bet...
(Date:11/8/2009)...t position promotes self-assurance, research finds...Your mother may have been right when she told you ...d posture could make you feel more confident about... sitting up straight gives a good impression to ot... and a psychology professor at Ohio State Universi...
(Date:11/8/2009)...8 Speaker Nancy Pelosi ...lowing the House passage of H.R. 3962, the Afforda...by a vote of 220 to 215. Below are the Speaker,s ...es just received a call from the President of the ...a great victory for the American people. I thank t...
Breaking Medicine News(10 mins):Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 2Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 3Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 4Health News:Few Change Medicare Plans Each Year, But Three Times as Many Are Considering a Change in 2010, Allsup Survey Finds, 5Health News:Young tennis players who play only 1 sport are more prone to injuries 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:Good Posture May Inspire Confidence 2
...e 47th Annual Meeting of the American Society for ...rado say that there is no direct link //between th...ess of prostate cancer, but the long-term survival...bsequent intensity of prostate cancer. Previous st...
...s the risk of colorectal tumours, while drinking w...study. // The study, conducted by Joseph C. A...sity, Stony Brook, New York, was meant to examine ...ients were subject to a survey of drinking habits ...
...from United Kingdom have found a new antibiotic ti...ation of Tetracycline known as Glycycline. // ... an increased incidence of antibiotic resistance s...tions in hospital. Staphylococcus aureus as shown ...
... interstitial fluid pressure (IFP) is negative, an... exposed, fluid does not seep out. //By contrast, ... barrier against efficient drug delivery into the ...itial space by convection (i.e. by streaming of a ...
...oor families who get fed in schools by the governm...ke up for their iron and vitamin deficiencies//. ...n pills, which have not found wide acceptance. Bes...a. The nutrition candy however should be seen as a...
...er is designated as the Breast Cancer Awareness Mo...hat despite the exponential morbidity and mortalit...d women are aware of what actually happens, what a...r Research Foundation, and Alexandra Penney, forme...
Other Medicine News:Health News:Alcohol Drinking Affects Risk Of Colorectal Tumours 2Health News:Tigecycline – New Generation Tetracycline With Broad Spectrum Antibacterial Activit 2Health News:A Novel Method For Measuring Interstitial Fluid Pressure In Cancer Tissues 2Health News:Vitamin filled nutrition candy for School children 2
Human Cardiac-Specific Troponin-I Enzyme Immunoassay (cTnI ELISA)
Acute Care Cardiac Troponin I
... brings true automation and continuous random acce...y sensitive assays for thyroid, anemia, cardiac, r...bolism testing are currently available, with infec... ECi can simultaneously process 60 accessible samp...
Myoglobin Test Modules
Medicine Products: